Plus, President Trump abandoned his hope of re-opening the U.S. economy by Easter as cases surge to more than 143,000, Macy’s said it is furloughing the majority of its 130,000 employees, and Johnson & Johnson said it will begin human trails on its experimental COVID-19 vaccine by September.
Read MorePlus, the $2 trillion stimulus bill has hit a snag in the House, the U.S. now has the most cases of the coronavirus in the world, and Novartis’ CEO said it’s “too soon” to say if two anti-malaria drugs will be an effective vaccine against the deadly virus.
Read MorePlus, the market is higher on optimism that a third stimulus bill will be finalized today, Gilead Sciences’ experimental COVID-19 treatment, remdesivir, received Orphan Drug Designation from the FDA, and General Motors said it is conserving cash and drawing down $16 billion from credit lines.
Read MorePlus, Senate republicans unveiled the third coronavirus relief package, California residents are under lockdown, and JPMorgan and Walmart are giving cash bonuses to front-line employees.
Read MorePlus, stocks’ volatile week continues, oil crashed to 18-year lows, and Apple announced new products.
Read MoreBuy Target – $2.75 or better Sell Target – TradersPro Sell Signal Summit Therapeutics plc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company’s lead product candidate is ridinilazole, an orally […]
Read MorePlus, the Trump administration is seeking a third coronavirus stimulus package, the WHO warns that the virus can in some cases survive in the air, and Cisco said that there have been 5.5 billion meeting minutes for its Webex video conferencing platform since the start of the month.
Read MorePlus, airlines could be in danger, and Regeneron and Sanofi are soon to begin human trials on a treatment for COVID-19.
Read MorePlus, Congress and the Trump Administration are nearing a coronavirus aid package, and the Fed began buying Treasurys.
Read MoreBuy Target – $5.50 or better Sell Target – TradersPro Sell Signal AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company’s products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat […]
Read MorePlus, Italy announced a nation-wide lockdown in an attempt to slow the spread of the coronavirus, Saudi Arabia and Russia escalated their oil price war, and Dick’s Sporting Goods is removing guns from another 440 stores.
Read MoreBuy Target – $3.75 or better Sell Target – TradersPro Sell Signal Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, […]
Read MorePlus, 30-year mortgage rates have fallen to their lowest level ever amid coronavirus fears, and an analyst says Gilead’s COVID-19 treatment only has a 50/50 chance, at best, of proving successful.
Read MoreBuy Target – $10.75 or better Sell Target – TradersPro Sell Signal BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered […]
Read MorePlus, activity in the U.S. services sector accelerated in February, GE said the coronavirus will impact Q1 earnings, and Arcturus Therapeutics shares are on the rise after the company joins the quest to find a COVID-19 vaccine.
Read More